Researchers report on ctDNA-based detection of residual disease prognostic for resected CRC
For patients with radically resected, stage II to IV colorectal cancer (CRC), circulating tumor (ct)DNA-based detection of molecular residual disease (MRD) in response to adjuvant chemotherapy (ACT) is prognostic of outcomes, ...
Jan 29, 2024
0
0